Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial

Baldomero, 2011, The EBMT activity survey 2009: trends over the past 5 years, Bone Marrow Transplant, 46, 485, 10.1038/bmt.2011.11 Sorror, 2005, Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia, Biol Blood Marrow Transplant, 11, 814, 10.1016/j.bbmt.2005.05.016 Arora, 2009, HLA-identical sibling compared with 8/8 matched and mismatched unrelated donor bone marrow transplant for chronic phase chronic myeloid leukemia, J Clin Oncol, 27, 1644, 10.1200/JCO.2008.18.7740 Dehn, 2008, Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match, Biol Blood Marrow Transplant, 14, 1334, 10.1016/j.bbmt.2008.09.009 Weisdorf, 2009, Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse, Biol Blood Marrow Transplant, 15, 1475, 10.1016/j.bbmt.2009.06.016 Gratwohl, 2011, Introduction of a quality management system and outcome after hematopoietic stem-cell transplantation, J Clin Oncol, 29, 1980, 10.1200/JCO.2010.30.4121 Pavletic, 2005, Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation, Blood, 106, 3308, 10.1182/blood-2005-04-1614 Bacigalupo, 2001, Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, 98, 2942, 10.1182/blood.V98.10.2942 Finke, 2009, Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, 10, 855, 10.1016/S1470-2045(09)70225-6 Lee, 2007, High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, Blood, 110, 4576, 10.1182/blood-2007-06-097386 Weisdorf, 2008, Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival, Biol Blood Marrow Transplant, 14, 748, 10.1016/j.bbmt.2008.04.003 Petersdorf, 2007, MHC haplotype matching for unrelated hematopoietic cell transplantation, PLoS Med, 4, e8, 10.1371/journal.pmed.0040008 Woolfrey, 2011, HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation, Biol Blood Marrow Transplant, 17, 885, 10.1016/j.bbmt.2010.09.012 Petersdorf, 1998, Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient, Blood, 92, 3515, 10.1182/blood.V92.10.3515 Sorror, 2004, Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities, Blood, 104, 961, 10.1182/blood-2004-02-0545 Sorror, 2007, Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences, Blood, 110, 4606, 10.1182/blood-2007-06-096966 Flowers, 2011, Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria, Blood, 117, 3214, 10.1182/blood-2010-08-302109 Eapen, 2007, Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival, Biol Blood Marrow Transplant, 13, 1461, 10.1016/j.bbmt.2007.08.006 Craddock, 2011, Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia, Leukemia, 25, 808, 10.1038/leu.2011.13 Craddock, 2010, Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia, Haematologica, 95, 989, 10.3324/haematol.2009.013920 Malard, 2010, Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation, Biol Blood Marrow Transplant, 16, 28, 10.1016/j.bbmt.2009.08.010 Simon, 1994, Statistical aspects of prognostic factor studies in oncology, Br J Cancer, 69, 979, 10.1038/bjc.1994.192 Socié, 2011, Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius, Blood, 117, 6375, 10.1182/blood-2011-01-329821 Kollman, 2001, Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age, Blood, 98, 2043, 10.1182/blood.V98.7.2043 Pulsipher, 2009, Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose, Blood, 114, 2606, 10.1182/blood-2009-03-208355 Anasetti, 2011, ASH Annual Meeting Abstracts, 118, 1 Soiffer, 2011, Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Blood, 117, 6963, 10.1182/blood-2011-01-332007 Marks, 2008, Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies, Blood, 112, 415, 10.1182/blood-2007-08-104745 Schmid, 2006, Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation, Blood, 108, 1092, 10.1182/blood-2005-10-4165 Platzbecker, 2006, Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia, Leukemia, 20, 707, 10.1038/sj.leu.2404143 Schlenk, 2010, Prospective evaluation of allogeneic hematopoietic stem-cell transplantation from matched related and matched unrelated donors in younger adults with high-risk acute myeloid leukemia: German-Austrian trial AMLHD98A, J Clin Oncol, 28, 4642, 10.1200/JCO.2010.28.6856